Los Angeles Capital Management LLC Trims Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Los Angeles Capital Management LLC lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 16.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 232,081 shares of the biopharmaceutical company’s stock after selling 44,800 shares during the quarter. Los Angeles Capital Management LLC owned about 0.40% of Vanda Pharmaceuticals worth $1,112,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets raised its stake in shares of Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 57,393 shares during the period. FMR LLC raised its stake in shares of Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock worth $702,000 after buying an additional 30,802 shares during the period. Massachusetts Financial Services Co. MA bought a new position in shares of Vanda Pharmaceuticals in the third quarter worth about $864,000. GSA Capital Partners LLP bought a new position in shares of Vanda Pharmaceuticals in the third quarter worth about $143,000. Finally, Barclays PLC raised its stake in shares of Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock worth $722,000 after buying an additional 86,677 shares during the period. Institutional investors own 88.14% of the company’s stock.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the company’s stock in a transaction on Friday, February 28th. The stock was acquired at an average cost of $4.76 per share, with a total value of $47,600.00. Following the purchase, the chief executive officer now directly owns 2,361,730 shares of the company’s stock, valued at approximately $11,241,834.80. This represents a 0.43 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders purchased 22,000 shares of company stock valued at $100,980 in the last 90 days. Insiders own 8.90% of the company’s stock.

Wall Street Analysts Forecast Growth

VNDA has been the topic of several research analyst reports. HC Wainwright boosted their price objective on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Up 1.3 %

Shares of Vanda Pharmaceuticals stock opened at $4.76 on Friday. The stock’s 50-day simple moving average is $4.59 and its 200-day simple moving average is $4.79. Vanda Pharmaceuticals Inc. has a 52 week low of $3.71 and a 52 week high of $6.75. The company has a market capitalization of $277.58 million, a price-to-earnings ratio of -14.88 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. On average, equities analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.